NanoVation Therapeutics Announces Multi-Year Partnership With Novo Nordisk To Develop Genetic Medicines Targeting Cardiometabolic And Rare Diseases, With Potential Payments Up To $600M And Tiered Royalties
NanoVation Therapeutics Announces Multi-Year Partnership With Novo Nordisk To Develop Genetic Medicines Targeting Cardiometabolic And Rare Diseases, With Potential Payments Up To $600M And Tiered Royalties
NanoVation Therapeutics宣佈與Novo Nordisk達成多年合作伙伴關係，共同開發針對心血管代謝疾病和罕見病的遺傳藥物，潛在支付高達6000萬美元的款項和分層專利權使用費。
NanoVation Therapeutics Announces Multi-Year Partnership With Novo Nordisk To Develop Genetic Medicines Targeting Cardiometabolic And Rare Diseases, With Potential Payments Up To $600M And Tiered Royalties
NanoVation Therapeutics宣佈與Novo Nordisk達成多年合作伙伴關係，共同開發針對心血管代謝疾病和罕見病的遺傳藥物，潛在支付高達6000萬美元的款項和分層專利權使用費。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。